Giuseppe Esposito

Dr. Giuseppe Esposito

General and HPB surgery, University of Modena and Reggio Emilia, Modena, Emilia-Romagna, Italy
orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 January 2025 in Cancers
Verified
Journal Article
Open access
PDF file
Giuseppe EspositoGiuseppe Esposito
Giuseppe Esposito
BMBarbara Mullineris
Barbara Mullineris
GCGiovanni Colli
Giovanni Colli
SCSerena Curia
Serena Curia
MPMicaela Piccoli
Micaela Piccoli
Background: Minimally invasive surgery (MIS) for adrenal glands is becoming increasingly developed worldwide and robotic surgery has advanced significantly. Although there are still concerns about the generalization of outcomes and the cost burden, the robotic platform shows several advantages in overcoming some laparoscopic shortcomings. Materials and Methods: A systematic review and meta-analysis were conducted using the PubMed, MEDLINE and Cochrane library databases of published articles comparing RA and LA up to January 2024. The evaluated endpoints were technical and post-operative outcomes. Dichotomous data were calculated using the odds ratio (OR), while continuous data were analyzed usingmean difference (MD) with a 95% confidence interval (95% CI). A random-effects model (REM) was applied. Results: By the inclusion of 28 studies, the meta-analysis revealed no statistically significant difference in the rates of intraoperative RBC transfusion, 30-day mortality, intraoperative and overall postoperative complications, re-admission, R1 resection margin and operating time in the RA group compared with the LA. However, the overall cost of hospitalization was significantly higher in the RA group than in the LA group, [MD USD 4101.32, (95% CI 3894.85, 4307.79) p < 0.00001]. With respect to the mean intraoperative blood loss, conversion to open surgery rate, time to first flatus and length of hospital stay, the RA group showed slightly statistically significant lower rates than the laparoscopic approach. Conclusions: To our knowledge, this is the largest and most recent meta-analysis that makes these comparisons. RA can be considered safe, feasible and comparable to LA in terms of the intraoperative and post-operative outcomes. In the near future, RA could represent a promising complementary approachto LA for benign and small malignant adrenal masses, particularly in high-volume referral centers specializing in robotic surgery. However, further studies are needed to confirm these findings.

16 July 2022 in Cancers
Verified
Journal Article
Open access
PDF file
GGGian Piero Guerrini
Gian Piero Guerrini
Giuseppe EspositoGiuseppe Esposito
Giuseppe Esposito
TOTiziana Olivieri
Tiziana Olivieri
PMPaolo Magistri
Paolo Magistri
RBRoberto Ballarin
Roberto Ballarin
FBFabrizio Di Benedetto
Fabrizio Di Benedetto
(1) Background: Primary liver transplantation (PLT) for HCC represents the ideal treatment. However, since organ shortage increases the risk of drop-out from the waiting list for tumor progression, a new surgical strategy has been developed: Salvage Liver Transplantation (SLT) can be offered as an additional curative strategy for HCC recurrence after liver resection. The aim of this updated meta-analysis is to compare surgical and long-term outcomes of SLT versus PLT for HCC. (2) Materials and Methods: A systematic review and meta-analysis was conducted using the published papers comparing SLT and PLT up to January 2022. (3) Results: 25 studies describing 11,275 patients met the inclusion criteria. The meta-analysis revealed no statistical difference in intraoperative blood loss, overall vascular complications, retransplantation rate, and hospital stay in the SLT group compared with the PLT group. However, the SLT group showed a slightly significant lower 5-year OS rate and 5-year disease-free survival rate. (4) Conclusion: meta-analysis advocates the relative safety and feasibility of both Salvage LT and Primary LT strategies. Specifically, SLT seems to have comparable surgical outcomes but slightly poorer long-term survival than PLT.

11 January 2024 in Cancers
Verified
Journal Article
Open access
PDF file
RBRoberto Ballarin
Roberto Ballarin
Giuseppe EspositoGiuseppe Esposito
Giuseppe Esposito
GGGian Piero Guerrini
Gian Piero Guerrini
PMPaolo Magistri
Paolo Magistri
BCBarbara Catellani
Barbara Catellani
FBFabrizio Di Benedetto
Fabrizio Di Benedetto
(1) Background: With ageing, the number of pancreaticoduodenectomies (PD) for benign or malignant disease is expected to increase in elderly patients. However, whether minimally invasive pancreaticoduodenectomy (MIPD) should be performed in the elderly is not clear yet and it is still debated. (2) Materials and Methods: A systematic review and meta-analysis was conducted including seven published articles comparing the technical and post-operative outcomes of MIPD in elderly versus younger patients up to December 2022. (3) Results: In total, 1378 patients were included in the meta-analysis. In term of overall and Clavien–Dindo I/II complication rates, post-operative pancreatic fistula (POPF) grade > A rates and biliary leakage, abdominal collection, post-operative bleeding and delayed gastric emptying rates, no differences emerged between the two groups. However, this study showed slightly higher intraoperative blood loss [MD 43.41, (95%CI 14.45, 72.38) p = 0.003], Clavien–Dindo ≥ III complication rates [OR 1.87, (95%CI 1.13, 3.11) p = 0.02] and mortality rates [OR 2.61, (95%CI 1.20, 5.68) p = 0.02] in the elderly compared with the younger group. Interestingly, as a minor endpoint, no differences in terms of the mean number of harvested lymphnode and of R0 resection rates were found. (4) Conclusion: MIPD seems to be relatively safe; however, there are slightly higher major morbidity, lung complication and mortality rates in elderly patients, who potentially represent the individuals that may benefit the most from the minimally invasive approach.

21 September 2021 in Cancers
Verified
Journal Article
Open access
PDF file
GGGian Piero Guerrini
Gian Piero Guerrini
Massimiliano BerrettaMassimiliano Berretta
Massimiliano Berretta
GGGiovanni Guaraldi
Giovanni Guaraldi
PMPaolo Magistri
Paolo Magistri
Giuseppe EspositoGiuseppe Esposito
Giuseppe Esposito
FBFabrizio Di Benedetto
Fabrizio Di Benedetto
Background: HIV-infected patients now have long life expectation since the introduction of the highly active antiretroviral therapy (HAART). Liver diseases, especially cirrhosis and hepatocellular carcinoma (HCC), currently represent a leading cause of death in this setting of patients. Aim: To address the results of liver transplantation (LT) for HCC in HIV-infected patients. Methods: All patients with and without HIV infection who underwent LT for HCC (n = 420) between 2001 and 2021 in our center were analyzed with the intent of comparing graft and patient survival. Cox regression analysis was used to determine prognostic survival factors and logistic regression to determine the predictor factors of post-LT recurrence. Results: Among 1010 LT, 32 were HIV-infected recipients. With an average follow-up of 62 ± 51 months, 5-year overall survival in LT recipients with and without HIV-infection was 71.6% and 69.9%, respectively (p = ns), whereas 5-year graft survival in HIV-infected and HIV-non infected was 68.3% and 68.2%, respectively (p = ns). The independent predictive factor of survival in the study group was: HCV infection (HR 1.83, p = 0.024). There were no significant differences in the pathological characteristics of HCC between the two groups. The logistic regression analysis of the study population demonstrated that microvascular invasion (HR 5.18, p< 0.001), HCC diameter (HR 1.16, p = 0.028), and number of HCC nodules (HR 1.26, p = 0.003) were predictors of recurrence post-LT. Conclusion: Our study shows that HIV patients undergoing LT for HCC have comparable results in terms of post-LT survival. Excellent results can be achieved for HIV-infected patients with HCC, as long as a strategy of close surveillance and precise treatment of the tumor is adopted while on the waiting list.

19 February 2025 in Artificial Organs
Verified
Journal Article
Closed access
PMPaolo Magistri
Paolo Magistri
SZSilvia Zamboni
Silvia Zamboni
BCBarbara Catellani
Barbara Catellani
CGCristiano Guidetti
Cristiano Guidetti
Giuseppe EspositoGiuseppe Esposito
Giuseppe Esposito
FBFabrizio Di Benedetto
Fabrizio Di Benedetto

5 September 2025 in Updates in Surgery
Verified
Journal Article
Closed access
PDF file
JMJacopo Mascherini
Jacopo Mascherini
PMPaolo Magistri
Paolo Magistri
CGCristiano Guidetti
Cristiano Guidetti
Giuseppe EspositoGiuseppe Esposito
Giuseppe Esposito
BCBarbara Catellani
Barbara Catellani
FBFabrizio Di Benedetto
Fabrizio Di Benedetto